BAJAJ BROKING
Cipla's Goa facility underwent a US FDA inspection, resulting in six Form 483 observations. The company aims to promptly address these within the set timeframe to resolve regulatory concerns, focusing on the areas of potential non-compliance with standards.
Cipla Ltd, a prominent pharmaceutical company, underwent an inspection by the US Food and Drug Administration (USFDA) at its manufacturing facility in Goa, spanning from June 10 to June 21, 2024. The outcome of this inspection included the issuance of six inspection observations documented in Form 483.
Form 483 is a significant regulatory document issued by the US FDA inspectors post-inspection. It lists observations made regarding deviations from current Good Manufacturing Practices (cGMP) at the inspected facility.
These observations are communicated to the company during a closing conference but do not constitute a final decision on compliance.
Explore: Cipla Share Price
Despite the observations, Cipla expressed its commitment to collaborating closely with the US FDA to address the identified issues comprehensively within the stipulated time frame. The company emphasised its dedication to resolving these matters promptly to maintain regulatory compliance and uphold quality standards.
Cipla, known for its global presence and focus on sustainable growth, operates in key markets including India, South Africa, North America, and other regulated and emerging markets.
The company's recent financial performance underscores its robust position in the pharmaceutical industry. Cipla reported a 79% increase in consolidated net profit to ₹939.04 crore and a 10% rise in revenue from operations to ₹6,163 crore in Q4 FY24 compared to Q4 FY23.
Disclaimer: Investments in the securities market are subject to market risk, read all related documents carefully before investing.
This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
For All Disclaimers Click Here: https://bit.ly/3Tcsfuc
Share this article:
7th Pay Commission Leave Rules & Holidays in India
11 Dec, 2024 | 5 Min. read
Wipro Ltd
11 Dec, 2024 | 7 Min. read
Aditya Birla Group
11 Dec, 2024 | 10 Min. read
What is the Lock-in Period in IPO
11 Dec, 2024 | 6 Min. read
Textile Sector in India
11 Dec, 2024 | 11 Min. read
Step-by-Step Guide to Accessing Your Income Tax Assessment Order Online
11 Dec, 2024 | 3 Min. read
IPO vs FPO vs OFS: Key Differences in How Companies Raise Capital
11 Dec, 2024 | 8 Min. read
Gold Price in India - Gold Prices Edge Higher as Futures Hit $2,654.50
11 Dec, 2024 | 39 Min. read
Indian Overseas Bank Secures ₹1,359 Crore Income Tax Refund for AY 2015-16
11 Dec, 2024 | 2 Min. read
HG Infra Secures ₹899 Crore NH-227B Road Upgrade Project in UP
11 Dec, 2024 | 2 Min. read
NTPC Green Energy Secures 500 MW Solar Project with 250 MW ESS from SECI
11 Dec, 2024 | 2 Min. read
Awfis Space ₹583 Crore Block Deal Launches at ₹680 Floor Price
11 Dec, 2024 | 2 Min. read
RBI Launches ULI: Transforming Loan Access
August 27, 2024 | 4 Min. read
Textile Sector in India
September 20, 2024 | 5 Min. read
List of IPOs with DRHPs Filed
November 30, 2023 | 3 Min. read
Aditya Birla Group
September 28, 2023 | 10 Min. read
Bajaj Housing Finance Ltd IPO: Things Smart Investors Need to Know
September 05, 2024 | 4 Min. read
Budget Stock Ideas 2024-2025 | Stocks to Buy Today
July 24, 2024 | 4 Min. read
IPO Eligibility Criteria : Full Details
March 15, 2024 | 6 Min. read
What Is the Lock-In Period in IPOs?
October 18, 2023 | 6 Min. read
Godfrey Phillips Announces 2:1 Bonus Shares
September 16, 2024 | 7 Min. read
Jindal Group- A Comprehensive Analysis
September 27, 2024 | 7 Min. read
Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading